ArticleDiabetes, obesity & metabolism2026
Cost-Effectiveness of NT-proBNP-Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real-World Evidence From the Hong Kong Diabetes Biobank.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cost-Effectiveness of NT-proBNP-Guided Cardiovascular Screening in Chinese Adults With Type 2 Diabetes: Real-World Evidence From the Hong Kong Diabetes Biobank.Diabetes, obesity & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsHeart failure (HF) is among the most costly and prevalent complications of type 2 diabetes (T2D), with annual incremental healthcare costs reaching US$12800 in Hong Kong. We evaluated the cost-effectiveness of NT-proBNP-guided cardiovascular risk stratification to guide cardioprotective treatment. MATERIALS AND
methodsWe developed a four-state Markov cohort model with transition probabilities estimated from the Hong Kong Diabetes Biobank (2014-2019). Patients were classified as low or high risk of HF based on NT-proBNP cut-offs of 400 and 125 pg/mL. The analysis was conducted from a payer's perspective over a lifetime horizon, utilising annual cycles and 2023 costs. Outcomes included incremental cost-effectiveness ratios (ICERs), life years (LY) and quality-adjusted life years (QALY), with a willingness-to-pay (WTP) threshold of USD 50889 to USD 152667 (1-3 × Hong Kong GDP per capita).
resultsNT-proBNP screening utilising 400 pg/mL was cost-saving (ICER: -USD $6558 per QALY) versus standard of care, yielding lower costs (-USD $846) and higher QALYs (0.129). The 125 pg/mL cut-off was cost-effective (ICER: USD $29 290 per QALY). Deterministic sensitivity analysis showed NT-proBNP specificity as the key driver of ICERs in both cut-offs. Probability Sensitivity Analysis results revealed a 100% probability of dominance for the 400 pg/mL cut-off and 98% for the 125 pg/mL cut-off at Hong Kong's willingness-to-pay thresholds (USD$50,889-152,667).
conclusionsUsing NT-proBNP to prioritise use of cardioprotective treatment on top of standard of care to reduce the risk of progression to HF in Chinese patients with T2D is cost-effective, supporting its integration into clinical practise.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.